18.26 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||17.56 x 1000|
|Ask||18.58 x 2000|
|Day's Range||17.74 - 18.77|
|52 Week Range||5.47 - 23.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2017 - Mar 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.25|
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer.” The publication appears in the April 23, 2018 online issue at https://www.nature.com/articles/s41591-018-0007-9 and will be published in a future print issue of Nature Medicine. “We are honored to have data from poziotinib published in this prestigious journal,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. For cancer patients that have exon 20 mutations, physicians have very few options.
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors ...
It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.
Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Spectrum Pharmaceuticals (SPPI) needs investors to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / April 11, 2018 / Spectrum Pharmaceuticals and Tandem Diabetes Care both exploded in Tuesday trading. Spectrum headed higher after announcing positive data from a phase 2 trial ...
Maxim raises BeiGene Ltd (NASDAQ: BGNE ) price target from $160 to $200; Says the company continues to advance its clinical pipeline with multiple catalysts ahead and a strong balance sheet with runway ...
Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant Non-Small Cell Lung Cancer study are available, based on longer follow-up.
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...
Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the H.C.
Surging implied volatility makes Spectrum Pharmaceuticals (SPPI) stock lucrative to the option traders.
Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / U.S. markets had a topsy-turvy day as concerns of a potential trade war, a result of tariffs proposed by President Donald Trump, continue to worry investors. ...
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Spectrum Pharmaceuticals and Portola Pharmaceuticals were two of the most active biotech stocks in the market on Tuesday. Spectrum reported its fourth quarter ...